Compare Fox Corp Class A (FOXA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Incyte Corporation — how do they compare? Fox Corp Class A trades at $61.87 (market cap $24.58B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Fox Corp Class A and Incyte Corporation are close in size by market cap, and Fox Corp Class A pays a 0.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FOXA | INCY | |
|---|---|---|
Market Cap | $24.58B | $24.54B |
Sector | Media | Health |
52-Week High | $76.11 | $129.93 |
52-Week Low | $48.79 | $81.61 |
Enterprise Value | $27.94B | $20.04B |
Dividend Yield | 0.93% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
